Please sign in to follow a disease.
Fabry disease
MONDO:0010526Fabry disease (FD) is a progressive, inherited, multisystemic lysosomal storage disease characterized by specific neurological, cutaneous, renal, cardiovascular, cochleo-vestibular and cerebrovascular manifestations.
Also known as: Alpha-galactosidase A deficiency, Anderson-Fabry disease, FD, Fabry disease, Fabry's disease, Fd, angiokeratoma corporis diffusum, diffuse angiokeratoma
96 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Promising enzyme therapy shows Long-Term safety for rare fabry disease
Disease control CompletedThis study looked at the long-term safety and effectiveness of a drug called pegunigalsidase alfa for adults with Fabry disease, a rare genetic condition. Participants received an infusion every four weeks for up to several years. The goal was to see if the drug is safe over time…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug shows promise for Long-Term cholesterol control
Disease control CompletedThis study looked at the long-term safety of a drug called ARO-APOC3 in adults with dyslipidemia (abnormal fat levels in the blood). Participants who completed a previous 12-month study could continue receiving the drug every 3 or 6 months. The goal was to see if the drug remains…
Phase: PHASE2 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Low-Dose statin shows promise for korean heart patients
Disease control CompletedThis study tested a low dose (10 mg) of the statin drug rosuvastatin in 242 Korean adults with high cholesterol or heart disease risk. The goal was to see how much it lowered 'bad' LDL cholesterol after 8 weeks. Results help guide cholesterol treatment in this population.
Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Can MRI reveal if enzyme therapy protects hearts in fabry disease?
Disease control CompletedThis study followed 26 people with Anderson-Fabry disease, some taking the enzyme replacement drug Replagal® and some not, to see how their hearts changed over two years. Researchers used special MRI scans to measure heart tissue relaxation time, which may indicate early damage. …
Phase: NA • Sponsor: University Hospital, Rouen • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
One-Time gene therapy could change fabry disease treatment
Disease control CompletedThis trial tested a new gene therapy called ST-920 for Fabry disease, a rare genetic condition. The therapy uses a harmless virus to deliver a working gene that helps the body produce an enzyme it's missing. 36 adults with Fabry disease received a single intravenous dose and were…
Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New enzyme therapy shows promise for Long-Term fabry disease management
Disease control CompletedThis study looked at the long-term safety of pegunigalsidase alfa, an enzyme replacement therapy, in 97 adults with Fabry disease. Participants received the drug intravenously every two weeks for up to several years. The main goal was to track side effects and see how well the dr…
Phase: PHASE3 • Sponsor: Chiesi Farmaceutici S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New fabry drug shows promise in small switch study
Disease control CompletedThis phase 3 trial tested a new version of the drug agalsidase beta (AGA BETA BS) in 20 people with Fabry disease who were already stable on the standard drug Fabrazyme. Participants switched to the new drug for 54 weeks to see if it worked just as well. The main goal was to keep…
Phase: PHASE3 • Sponsor: Bio Sidus SA • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for fabry patients: Long-Term drug safety confirmed
Disease control CompletedThis study looked at the long-term safety of a drug called migalastat in 16 people over age 12 with Fabry disease, a rare genetic disorder. Participants had already completed an earlier study and continued taking migalastat to see if it was safe and how it affected kidney functio…
Phase: PHASE3 • Sponsor: Amicus Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
HIV heart risk targeted: new drug shows promise in reducing arterial inflammation
Disease control CompletedThis study tested whether a drug called alirocumab, which lowers cholesterol, can reduce heart disease risk in people with HIV. The trial involved 118 adults aged 40 and older with well-controlled HIV and high heart disease risk. Participants received either alirocumab or a place…
Phase: PHASE3 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug aims to lower dangerous fats in the blood
Disease control CompletedThis early-stage study tested a new medicine called ARO-ANG3 in 93 people, including healthy volunteers and patients with high cholesterol or high triglycerides. The main goal was to check if the drug is safe and how the body processes it. This research helps determine if the dru…
Phase: PHASE1 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New chemo combo may lower death risk in child stem cell transplants
Disease control CompletedThis study tested two different chemotherapy drugs (Treosulfan and Busulfan) given before a stem cell transplant in 106 children with serious non-cancer diseases like immune disorders, metabolic diseases, blood disorders, and bone marrow failure. The goal was to see which drug le…
Phase: PHASE2 • Sponsor: medac GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Can a quicker infusion make fabry treatment less burdensome?
Disease control CompletedThis study tested whether giving Fabrazyme, a lifelong enzyme replacement therapy for Fabry disease, at a faster infusion rate is safe and tolerable. Eight patients who had been on Fabrazyme without recent reactions participated. The goal was to see if shortening infusion time co…
Phase: PHASE4 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Fabrazyme shows promise for fabry disease in chinese study
Disease control CompletedThis study tested the safety and effectiveness of Fabrazyme (agalsidase beta) in 22 Chinese patients with Fabry disease, a rare genetic disorder. Participants received enzyme replacement therapy through IV infusions over 54 weeks. The study monitored side effects and changes in d…
Phase: PHASE4 • Sponsor: Genzyme, a Sanofi Company • Aim: Disease control
Last updated Jun 26, 2026 15:35 UTC
-
New MRI scan could spot kidney trouble early in fabry patients
Diagnosis CompletedThis study tested whether a special MRI scan called T1 mapping can detect kidney damage in people with Fabry disease, a rare genetic disorder. Researchers compared MRI results from 70 adults with and without Fabry disease. The goal was to see if this non-invasive scan could help …
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 13:01 UTC
-
Hidden genetic disorder found in chronic pain patients?
Diagnosis CompletedThis study tested 776 people with chronic pain of unknown cause to see if they had Fabry disease, a rare inherited disorder that can cause pain, kidney, heart, and nerve problems. Researchers used enzyme tests in men and genetic tests in women to find cases. The goal was to see h…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
New metabolomic test could spot rare metabolic diseases faster
Diagnosis CompletedThis study tested a new method called global metabolomic profiling to diagnose inborn errors of metabolism, a group of rare genetic disorders. Researchers compared this approach to traditional testing in 240 participants. The goal was to see if the new method could more accuratel…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:53 UTC
-
New registry tracks pregnancy in women with rare metabolic diseases
Knowledge-focused CompletedThis study created a registry of medical records from women with inborn errors of metabolism—rare conditions that affect how the body turns food into energy. Researchers collected data from past or current pregnancies and followed babies for one year after birth. The goal was to …
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Gene hunt for rare cholesterol problems
Knowledge-focused CompletedThis study aimed to find new gene changes that cause rare lipid disorders. Researchers used advanced genetic testing to look at many genes at once in 140 people and their relatives. The goal was to discover causes that older methods missed.
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Study explores how family and friends impact caregiver health
Knowledge-focused CompletedThis completed study looked at how the social networks of caregivers affect their stress and health when caring for someone with an inherited disease. Researchers surveyed over 680 participants, including family members and formal caregivers, to understand caregiving burden and s…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Scientists probe fat particles to unlock heart disease secrets
Knowledge-focused CompletedThis study looked at how fat-carrying particles called lipoproteins work in healthy people and those with high cholesterol or other lipid disorders. Researchers injected tiny, safe amounts of radioactive lipoproteins to track them in the body. The goal was to better understand ho…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
Heart study reveals hidden link between blood vessels and muscle blockage
Knowledge-focused CompletedThis study looked at how blood vessel function relates to heart blockage in people with a genetic heart condition called hypertrophic cardiomyopathy. Researchers measured blood flow and vessel flexibility in 40 adults. The goal was to understand the connection, not to test a trea…
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Could fabry disease be a hidden cause of chronic pain?
Knowledge-focused CompletedThis study tested 137 people with chronic pain of unknown cause to see if they had Fabry disease, a rare genetic disorder. Researchers used blood tests to check for the condition. The goal was to find out how common Fabry disease is in this group and help diagnose it earlier.
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Heart condition costs under the microscope in massive hospital study
Knowledge-focused CompletedThis study collected information from over 15,000 people hospitalized with cardiomyopathy, a heart muscle disease. Researchers looked at how much these hospital stays cost and what the money was spent on. The goal was to understand the real-world financial impact and help manage …
Sponsor: China National Center for Cardiovascular Diseases • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Scientists probe hidden link between blood protein and heart disease
Knowledge-focused CompletedThis study looked at 99 people with high heart risk to understand how a protein called CETP affects plaque buildup in arteries. Researchers measured CETP activity, artery thickness, and calcium scores. The goal was to learn more about heart disease, not to test a new treatment.
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Fabry patients wear tech to uncover hidden links between activity, sleep, and Well-Being
Knowledge-focused CompletedThis completed study monitored 100 adults with Fabry disease using a wearable device and questionnaires to measure physical activity, sleep, and quality of life. The goal was to understand how daily movement and rest relate to anxiety, depression, and overall well-being. No treat…
Sponsor: Royal Free Hospital NHS Foundation Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
AI could spot rare fabry disease from hospital records
Knowledge-focused CompletedThis study aims to develop a computer algorithm that can detect Fabry disease earlier by analyzing hospital electronic health records. Researchers will look at data from the past 10 years to see if they can identify patients with Fabry disease using a ranking system. No drugs or …
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
15-Year checkup: how did early fabry treatment hold up?
Knowledge-focused CompletedThis study checked in on 5 adults with Fabry disease who had been taking enzyme replacement therapy (ERT) since childhood for about 15 years. Researchers measured kidney function and heart health to see how well the long-term treatment worked. The goal was to gather follow-up dat…
Phase: NA • Sponsor: Baylor Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Gene sequencing uncovers mysterious fetal malformations
Knowledge-focused CompletedThis study tested whether a powerful DNA test called high-throughput exome sequencing can find genetic causes of multiple birth defects in fetuses when standard exams fail. Researchers studied 100 fetuses with at least two malformations and no prior diagnosis. They compared the n…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
How much time does fabry treatment really take? new study measures the burden
Knowledge-focused CompletedThis completed study looked at how much time healthcare professionals spend preparing and giving enzyme replacement therapy (ERT) to adults with Fabry disease. It also measured the impact on patients and their caregivers, including time, costs, and quality of life. The goal was t…
Sponsor: Amicus Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Speedy gene test aims to give answers on birth defects in just 7 days
Knowledge-focused CompletedThis study tested whether a fast type of genetic test called rapid genome sequencing can find the cause of birth defects seen on ultrasound more quickly than current methods. Researchers included 184 pregnancies with certain ultrasound findings. The goal was to see if results cou…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Study reveals HPV vaccine gaps in teens with chronic illness
Knowledge-focused CompletedThis study looked at how many girls and young women aged 11 to 20 with chronic diseases (like diabetes or immune conditions) got the HPV vaccine, compared to those without chronic illness. Researchers reviewed records of 223 participants from a hospital in France. The goal was to…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
New version of fabry drug tested against Brand-Name in healthy volunteers
Knowledge-focused CompletedThis early study tested whether a new version of the enzyme replacement drug agalsidase beta (made by Biosidus) works similarly to the approved drug Fabrazyme. Twenty-four healthy men received a single infusion of one of the two drugs. Researchers measured how the drug moved thro…
Phase: PHASE1 • Sponsor: Bio Sidus SA • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
Hidden genetic heart condition sought in 409 portuguese patients
Knowledge-focused CompletedThis study looked for Fabry disease, a rare genetic disorder, in 409 Portuguese adults with unexplained heart muscle diseases. Researchers tested patients with different types of cardiomyopathy to see how many actually had Fabry disease. The goal was to better understand how comm…
Sponsor: Universidade do Porto • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:53 UTC